Theralase Technologies Inc. (TLT)

Currency in CAD
0.210
-0.010(-4.55%)
Closed·
TLT Scorecard
Full Analysis
Net income is expected to grow this year
TLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.2100.220
52 wk Range
0.1550.380
Key Statistics
Bid/Ask
0.205 / 0.22
Prev. Close
0.22
Open
0.22
Day's Range
0.21-0.22
52 wk Range
0.155-0.38
Volume
13.46K
Average Volume (3m)
73.41K
1-Year Change
12.82%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.700
Upside
+233.33%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Theralase Technologies Inc. Company Profile

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

Theralase Technologies Inc. Earnings Call Summary for Q1/2025

  • Theralase Technologies missed Q1 2025 forecasts with EPS of -0.006 and revenue of $91,190, leading to a 9.52% stock drop to $0.19
  • Revenue declined to $91,000 from $175,000 YoY, with increased operating expenses in administration and R&D
  • Company aims to complete clinical studies, targeting FDA and Health Canada applications by Q4 2026 and potential approval in early 2027
  • CEO emphasized focus on light-activated therapeutics, highlighting Ruvedar's efficacy and pursuing debt financing to reduce dilution
  • Financial challenges persist, with $8-10 million needed for clinical studies and efforts to secure non-dilutive funding ongoing
Last Updated: 09/06/2025, 16:48
Read Full Transcript

Compare TLT to Peers and Sector

Metrics to compare
TLT
Peers
Sector
Relationship
P/E Ratio
−12.7x−5.3x−0.5x
PEG Ratio
−1.56−0.260.00
Price/Book
51.9x0.0x2.6x
Price / LTM Sales
59.6x16.8x3.3x
Upside (Analyst Target)
218.2%460.1%43.5%
Fair Value Upside
Unlock−11.4%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.700
(+233.33% Upside)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-0.006 / -0.003
Revenue / Forecast
91.19K / 200.00K
EPS Revisions
Last 90 days

TLT Income Statement

FAQ

What Stock Exchange Does Theralase Technologies Trade On?

Theralase Technologies is listed and trades on the TSX Venture Exchange stock exchange.

What Is the Stock Symbol for Theralase Technologies?

The stock symbol for Theralase Technologies is "TLT."

What Is the Theralase Technologies Market Cap?

As of today, Theralase Technologies market cap is 110.19M.

What Is Theralase Technologies's Earnings Per Share (TTM)?

The Theralase Technologies EPS (TTM) is -0.02.

When Is the Next Theralase Technologies Earnings Date?

Theralase Technologies will release its next earnings report on 31 Aug 2025.

From a Technical Analysis Perspective, Is TLT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Theralase Technologies Stock Split?

Theralase Technologies has split 0 times.

How Many Employees Does Theralase Technologies Have?

Theralase Technologies has 20 employees.

What is the current trading status of Theralase Technologies (TLT)?

As of 07 Aug 2025, Theralase Technologies (TLT) is trading at a price of 0.21, with a previous close of 0.22. The stock has fluctuated within a day range of 0.21 to 0.22, while its 52-week range spans from 0.16 to 0.38.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.